v3.26.1
Condensed Consolidated Statements of Changes in Mezzanine Equity and Stockholder's Equity (Deficit) - USD ($)
$ in Thousands
Total
Series A Convertible Preferred Stock
Series B Convertible Preferred Stock
Redeemable Common Stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024   11,479 9,250 750,000      
Beginning balance at Dec. 31, 2024   $ 5,151 $ 3,452 $ 4,334      
Increase (Decrease) in Temporary Equity [Roll Forward]              
Accretion on convertible preferred stock   $ 500 $ 348        
Accretion on redeemable common stock       $ 21      
Conversion of preferred stock (in shares)   0          
Accretion on redeemable common stock   $ 0          
Forfeiture of redeemable common stock (in shares)       (62,500)      
Ending balance (in shares) at Mar. 31, 2025   11,479 9,250 687,500      
Ending balance at Mar. 31, 2025   $ 5,651 $ 3,800 $ 4,355      
Beginning balance (in shares) at Dec. 31, 2024         15,725,783    
Beginning balance at Dec. 31, 2024 $ (29,751)       $ 2 $ 238,442 $ (268,195)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Accretion on convertible preferred stock (847)         (847)  
Accretion on redeemable common stock (21)         (21)  
Common stock issuance costs 7         7  
Issuance of common stock for restricted stock units vesting (in shares)         56,149    
Issuance of common stock for employee stock purchase plans (in shares)         26,917    
Issuance of common stock for employee stock purchase plan 97         97  
Stock-based compensation 1,684         1,684  
Net income (loss) 3,025           3,025
Ending balance (in shares) at Mar. 31, 2025         15,808,849    
Ending balance at Mar. 31, 2025 (25,806)       $ 2 239,362 (265,170)
Beginning balance (in shares) at Dec. 31, 2025   11,479 9,250 562,500      
Beginning balance at Dec. 31, 2025 16,413 $ 7,151 $ 4,844 $ 4,418      
Increase (Decrease) in Temporary Equity [Roll Forward]              
Accretion on convertible preferred stock   $ 500 $ 348        
Accretion on redeemable common stock       $ 13      
Ending balance (in shares) at Mar. 31, 2026   11,479 9,250 252,500      
Ending balance at Mar. 31, 2026 14,835 $ 7,651 $ 5,192 $ 1,992      
Beginning balance (in shares) at Dec. 31, 2025         26,945,426    
Beginning balance at Dec. 31, 2025 19,042       $ 3 326,912 (307,873)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Accretion on convertible preferred stock (848)         (848)  
Accretion on redeemable common stock (13)         (13)  
Conversion of redeemable common stock to common stock (in shares)       (310,000) 310,000    
Conversion of redeemable common stock to common stock 2,439     $ (2,439)      
Issuance of common stock for restricted stock units vesting (in shares)         800,186    
Issuance of common stock for employee stock purchase plans (in shares)         34,787    
Issuance of common stock for employee stock purchase plan 148         148  
Exercises of options (in shares)         8,713    
Issuance of common stock upon exercise of stock options 37         37  
Stock-based compensation 3,542         3,542  
Net income (loss) (3,336)           (3,336)
Ending balance (in shares) at Mar. 31, 2026         28,099,112    
Ending balance at Mar. 31, 2026 $ 21,011       $ 3 $ 332,217 $ (311,209)